Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy: A Multinational Prospective Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Breast Cancer Screening and Diagnosis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Cardiovascular risks associated with protease inhibitors for the treatment of HIV

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period: The EuroSIDA study, 1996 to 2015

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Frédérique Chammartin
  • Sara Lodi
  • Roger Logan
  • Lene Ryom
  • Amanda Mocroft
  • Ole Kirk
  • Antonella d'Arminio Monforte
  • Peter Reiss
  • Andrew Phillips
  • Wafaa El-Sadr
  • Camilla I Hatleberg
  • Christian Pradier
  • Fabrice Bonnet
  • Matthew Law
  • Stéphane De Wit
  • Caroline Sabin
  • Jens D Lundgren
  • Heiner C Bucher
Vis graf over relationer

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 109 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear.

OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.

DESIGN: Multinational prospective cohort study.

SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included HIV-positive persons from Europe, Australia, and the United States.

PARTICIPANTS: 8318 HIV-positive persons with at least 1 measurement each of CD4 cell count and viral load while ART-naive (study period, 2006 to 2016).

MEASUREMENTS: The parametric g-formula was used, with adjustment for baseline and time-dependent confounders (CD4 cell count and viral load), to assess the 10-year risk for non-AIDS-defining and AIDS-defining cancer of immediate versus deferred (at CD4 counts <350 and <500 × 109 cells/L) ART initiation strategies.

RESULTS: During 64 021 person-years of follow-up, 231 cases of non-AIDS-defining cancer and 272 of AIDS-defining cancer occurred among HIV-positive persons with a median age of 36 years (interquartile range, 29 to 43 years). With immediate ART, the 10-year risk for non-AIDS-defining cancer was 2.97% (95% CI, 2.37% to 3.50%) and that for AIDS-defining cancer was 2.50% (CI, 2.37% to 3.38%). Compared with immediate ART initiation, the 10-year absolute risk differences when deferring ART to CD4 counts less than 500 × 109 cells/L and less than 350 × 109 cells/L were 0.12 percentage point (CI, -0.01 to 0.26 percentage point) and 0.29 percentage point (CI, -0.03 to 0.73 percentage point), respectively, for non-AIDS-defining cancer and 0.32 percentage point (CI, 0.21 to 0.44 percentage point) and 1.00 percentage point (CI, 0.67 to 1.44 percentage points), respectively, for AIDS-defining cancer.

LIMITATION: Potential residual confounding due to observational study design.

CONCLUSION: In this young cohort, effects of immediate ART on 10-year risk for cancer were small, and further supportive data are needed for non-AIDS-defining cancer.

PRIMARY FUNDING SOURCE: Highly Active Antiretroviral Therapy Oversight Committee.

OriginalsprogEngelsk
TidsskriftAnnals of Internal Medicine
Vol/bind174
Udgave nummer6
Sider (fra-til)768-776
Antal sider9
ISSN0003-4819
DOI
StatusUdgivet - jun. 2021

ID: 64485367